US FDA approved chemical cousin of dissociative psychedelic ketamine to treat depression
Earlier today, the FDA approved esketamine (brand name Spravato), a relative of the dissociative psychedelic/anaesthetic ketamine (Special K), as a treatment for depression. Spravato comes in nasal spray form meant to be administered weekly or every other week depending on the severity of the patient's depression.
"There has been a longstanding need for additional ...